China
Africa
Explore chapters and articles related to this topic
Antiasthma Agents during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Chapter 11 covers antihistamine and expectorant use during pregnancy. The following relevant medications are included in Chapter 11: brompheniramine, cetirizine, chlorpheniramine, dexchlorpheniramine, diphenhydramine, hydroxyzine, loratadine, oxymetazoline, pheniramine, phenylephrine, pseudoephedrine, tripelennamine and triprolidine are generally considered safe for use during pregnancy. Some literature suggests that expectorants and mucolytics have efficacy for asthma treatment.
Pharmacokinetic-Pharmacodynamic Correlations of Antihistamines
Published in Hartmut Derendorf, Günther Hochhaus, Handbook of Pharmacokinetic/Pharmacodynamic Correlation, 2019
Eric Snoeck, Achiel Van Peer, Jos Heykants
After a single oral dose of 0.04 mg/kg given to seven healthy adults, triprolidine appeared to be well absorbed with peak serum concentrations reached within 1 to 2 h after dosing.55 The terminal half-life of triprolidine averaged 2.1 h, which is extremely short. No significant wheal suppression could be observed after a single oral intake of triprolidine. Although the inhibition of the flare response was statistically significant at 2, 3, 6, and 8 h postdosing, the amount of suppression was small. The dose of triprolidine administered in this study is the initial dose of the drug usually recommended for adults.60 Histamine-induced skin reactions were more inhibited after higher doses of triprolidine.61 At 12 h after intake of an oral 10-mg dose of triprolidine, wheal and flare sizes were suppressed for approximately 90%.61 However, even a single 2.5-mg dose of triprolidine produced drowsiness in five of the seven subjects.55
Information on level of drugs into breastmilk
Published in Wendy Jones, Breastfeeding and Medication, 2013
Aljazaf K, HaleTW, Ilett KF, Hartmann PE, Mitoulas LR, Kristensen JH, Hackett LP. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk, Br J Clin Pharmacol, 2003;56(1):18–24. Findlay JW, Butz RF, Sailstad JM, Warren JT, Welch RM, Pseudoephedrine and triprolidine in plasma and breastmilk of nursing mothers, Br J Clin Pharmacol, 1984;18:901–6. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G, Prospective follow-up of adverse reactions in breastfed infants exposed to maternal medication, Am J Obstet Gynecol, 1993;168:1393–9.
The clinical relationship between histamine-1 receptor antagonists and risk of cancer: a systematic review and meta-analysis
Published in Expert Review of Anticancer Therapy, 2023
Elham Bakhtiari, Nasrin Moazzen, Amir Amirabadi, Hamid Ahanchian
The risk of cancer was investigated in all case-control studies [10,13,16–18]. The risk of breast cancer was investigated in two studies [16,18]. Kelly et al. [16] studied the risk of breast cancer according to use of antihistamines in 11,628 women. Relative risk was estimated for regular use of antihistamines (>4 days per week for equal to or more than 4 weeks beginning equal to or more than 1 year before admission). Antihistamines studied included chlorpheniramine, doxylamine, triprolidine, brompheniramine, terfenadine, hydroxyzine, diphenhydramine, pyrllamlne, phenyttoxamine, cyproheptadlne, dexbrompheniramine, methapyrilene, astemizole, clemastine, dimethindene, antazoline, promethazlne, pyrrobutamlne, carblnoxamine, pheniramine, dimennydrtnate, tripelennamine, thenyldiamlne, loratadine, trimethobenzamide, pyribenzamine, trimeprazine, and other ones. The cancer risk was calculated according to type and duration of antihistamines. Duration were including less than 1 year, 1–4 years, 5–9 years, and equal to or more than 10 years. The risk of cancer was not associated with the type of antihistamines. In duration of more than 10 years, the risk of cancer was 0.5 (0.95% CI = (0.3–0.8)).
Oculo-auriculo-vertebral spectrum and maternal drug ingestion: cause or coincidence?
Published in Hearing, Balance and Communication, 2023
Joana Raquel Costa, Miguel Bebiano Coutinho, Teresa Soares, Luís Meireles
Fluoxetine intake during pregnancy was observed in 3 cases. One case throughout the first trimester of pregnancy and the second case during the first and second trimester. In two cases, a history of Gestational Diabetes requiring insulin in the third trimester was found. The use of Hormonal Contraceptives with oestrogen and progesterone components during the first trimester of pregnancy has been reported in 4 cases: Perlutan® – algestone acetophenide + oestradiol enanthade; Provera® – medroxyprogesterone acetate; and Harmonet® – ethinylestradiol + gestodene (2 cases). In two cases, a history of Hypothyroidism requiring Levothyroxine intake was reported. Also in two cases, history of intake of Isotretinoin during the first trimester of pregnancy for the treatment of acne has been described. Other drugs reported were: Domperidone (until the fifth week of gestation); Enalapril; Acyclovir (in the seventh week for herpes zoster) and Pseudoephedrine/Triprolidine.
A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism
Published in Xenobiotica, 2022
Daniel J. Weston, Mehul Dave, Kevin Colizza, Steve Thomas, Laura Tomlinson, Richard Gregory, Claire Beaumont, Jill Pirhalla, Gordon J. Dear
Drug compounds (7-ethoxycoumarin, dextromethorphan, diazepam, diflunisal, domperidone, flumazenil, imipramine, ketoprofen, nifedipine, phenacetin, phenytoin, tenoxicam, tolbutamide, triprolidine, verapamil, warfarin) were provided either by GSK internal compound management services or purchased externally (Sigma Aldrich, Poole, UK). Structures of parent drug compounds are shown in the Supplemental Figure S1. Novel GSK compounds used in real-world application of this workflow were provided by GSK internal compound management. Mobile phases were made using 1 L of UHPLC grade water (Riedel-de Haen) or 1 L of UHPLC grade acetonitrile (Riedel-de Haen) in sealed glass bottles (both from Honeywell, Bracknell, UK) to which was added ultra-pure formic acid (1 mL) from break-neck vials (Waters, Manchester, UK) before manual mixing to give mobile phase A (0.1% (v/v) formic acid (aqueous)) and mobile phase B (0.1% (v/v) formic acid in acetonitrile), respectively. Other sample preparation solvents and chromatographic wash solvents consisted of water and acetonitrile (both as above) or methanol (Ultra-Pure Grade, CromSil, UK). A multi-analyte LCMS QC stock solution (Waters, Manchester, UK) was used for system suitability testing. The mass spectrometers were calibrated as required using Pierce LTQ-Velos Calibration Mix in either positive-ion or negative-ion mode (ThermoFisher Scientific, San Jose, CA).